Diuretic response in patients with acute decompensated heart failure

Characteristics and clinical outcome - An analysis from RELAX-AHF

Adriaan A. Voors, Beth A. Davison, John R. Teerlink, G. Michael Felker, Gad Cotter, Gerasimos Filippatos, Barry H. Greenberg, Peter Pang, Bruce Levin, Tsushung A. Hua, Thomas Severin, Piotr Ponikowski, Marco Metra

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Aims We studied the characteristics and clinical outcome related to diuretic response and the effects of serelaxin in patients hospitalized for acute heart failure (AHF).

Methods and results RELAX-AHF was a double-blind, placebo-controlled trial, enrolling 1161 patients admitted to hospital for AHF who were randomized to 48 h i.v infusions of placebo or serelaxin (30 μg/kg per day) within 16 h from presentation. Diuretic response was defined as Δ weight kg/[(total i.v. dose)/40 mg] + [(total oral dose)/80 mg)] furosemide (or equivalent loop diuretic dose) up to day 5. Median diuretic response was -0.42 (-1.00, -0.14) kg/40 mg. A poor diuretic response was independently associated with Western-like region (Western Europe, North America, Israel, and Poland), lower diastolic blood pressure, the absence of oedema, higher blood urea nitrogen, and lower levels of aspartate aminotransferase and potassium (all P <0.01). Randomization to serelaxin was associated with lower doses of i.v. loop diuretics and slightly less weight loss, resulting in a neutral effect on diuretic response. Worse diuretic response was independently associated both with less relief of dyspnoea, measured with a visual analogue scale (VAS) at day 5 (primary endpoint; P = 0.0002), and with a higher risk of cardiovascular death or rehospitalization for heart failure or renal failure through day 60 (secondary endpoint, P <0.0001), but not with increased 180-day cardiovascular mortality (P = 0.507).

Conclusions In patients hospitalized for AHF, a poor diuretic response was associated with a poor in-hospital and early post-discharge clinical outcome. Serelaxin had a neutral effect on diuretic response. Trial registration: NCT00520806.

Original languageEnglish (US)
Pages (from-to)1230-1240
Number of pages11
JournalEuropean Journal of Heart Failure
Volume16
Issue number11
DOIs
StatePublished - Nov 1 2014
Externally publishedYes

Fingerprint

Diuretics
Heart Failure
Sodium Potassium Chloride Symporter Inhibitors
Placebos
Blood Pressure
Blood Urea Nitrogen
Furosemide
Israel
Poland
Random Allocation
Aspartate Aminotransferases
North America
Visual Analog Scale
Dyspnea
Renal Insufficiency
Weight Loss
Edema
Potassium
Weights and Measures
Mortality

Keywords

  • Diuretic response
  • Heart failure
  • Renal function

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Medicine(all)

Cite this

Voors, A. A., Davison, B. A., Teerlink, J. R., Felker, G. M., Cotter, G., Filippatos, G., ... Metra, M. (2014). Diuretic response in patients with acute decompensated heart failure: Characteristics and clinical outcome - An analysis from RELAX-AHF. European Journal of Heart Failure, 16(11), 1230-1240. https://doi.org/10.1002/ejhf.170

Diuretic response in patients with acute decompensated heart failure : Characteristics and clinical outcome - An analysis from RELAX-AHF. / Voors, Adriaan A.; Davison, Beth A.; Teerlink, John R.; Felker, G. Michael; Cotter, Gad; Filippatos, Gerasimos; Greenberg, Barry H.; Pang, Peter; Levin, Bruce; Hua, Tsushung A.; Severin, Thomas; Ponikowski, Piotr; Metra, Marco.

In: European Journal of Heart Failure, Vol. 16, No. 11, 01.11.2014, p. 1230-1240.

Research output: Contribution to journalArticle

Voors, AA, Davison, BA, Teerlink, JR, Felker, GM, Cotter, G, Filippatos, G, Greenberg, BH, Pang, P, Levin, B, Hua, TA, Severin, T, Ponikowski, P & Metra, M 2014, 'Diuretic response in patients with acute decompensated heart failure: Characteristics and clinical outcome - An analysis from RELAX-AHF', European Journal of Heart Failure, vol. 16, no. 11, pp. 1230-1240. https://doi.org/10.1002/ejhf.170
Voors, Adriaan A. ; Davison, Beth A. ; Teerlink, John R. ; Felker, G. Michael ; Cotter, Gad ; Filippatos, Gerasimos ; Greenberg, Barry H. ; Pang, Peter ; Levin, Bruce ; Hua, Tsushung A. ; Severin, Thomas ; Ponikowski, Piotr ; Metra, Marco. / Diuretic response in patients with acute decompensated heart failure : Characteristics and clinical outcome - An analysis from RELAX-AHF. In: European Journal of Heart Failure. 2014 ; Vol. 16, No. 11. pp. 1230-1240.
@article{4c54a1cc7bf54b98941452b0435e8ed0,
title = "Diuretic response in patients with acute decompensated heart failure: Characteristics and clinical outcome - An analysis from RELAX-AHF",
abstract = "Aims We studied the characteristics and clinical outcome related to diuretic response and the effects of serelaxin in patients hospitalized for acute heart failure (AHF).Methods and results RELAX-AHF was a double-blind, placebo-controlled trial, enrolling 1161 patients admitted to hospital for AHF who were randomized to 48 h i.v infusions of placebo or serelaxin (30 μg/kg per day) within 16 h from presentation. Diuretic response was defined as Δ weight kg/[(total i.v. dose)/40 mg] + [(total oral dose)/80 mg)] furosemide (or equivalent loop diuretic dose) up to day 5. Median diuretic response was -0.42 (-1.00, -0.14) kg/40 mg. A poor diuretic response was independently associated with Western-like region (Western Europe, North America, Israel, and Poland), lower diastolic blood pressure, the absence of oedema, higher blood urea nitrogen, and lower levels of aspartate aminotransferase and potassium (all P <0.01). Randomization to serelaxin was associated with lower doses of i.v. loop diuretics and slightly less weight loss, resulting in a neutral effect on diuretic response. Worse diuretic response was independently associated both with less relief of dyspnoea, measured with a visual analogue scale (VAS) at day 5 (primary endpoint; P = 0.0002), and with a higher risk of cardiovascular death or rehospitalization for heart failure or renal failure through day 60 (secondary endpoint, P <0.0001), but not with increased 180-day cardiovascular mortality (P = 0.507).Conclusions In patients hospitalized for AHF, a poor diuretic response was associated with a poor in-hospital and early post-discharge clinical outcome. Serelaxin had a neutral effect on diuretic response. Trial registration: NCT00520806.",
keywords = "Diuretic response, Heart failure, Renal function",
author = "Voors, {Adriaan A.} and Davison, {Beth A.} and Teerlink, {John R.} and Felker, {G. Michael} and Gad Cotter and Gerasimos Filippatos and Greenberg, {Barry H.} and Peter Pang and Bruce Levin and Hua, {Tsushung A.} and Thomas Severin and Piotr Ponikowski and Marco Metra",
year = "2014",
month = "11",
day = "1",
doi = "10.1002/ejhf.170",
language = "English (US)",
volume = "16",
pages = "1230--1240",
journal = "European Journal of Heart Failure",
issn = "1388-9842",
publisher = "Oxford University Press",
number = "11",

}

TY - JOUR

T1 - Diuretic response in patients with acute decompensated heart failure

T2 - Characteristics and clinical outcome - An analysis from RELAX-AHF

AU - Voors, Adriaan A.

AU - Davison, Beth A.

AU - Teerlink, John R.

AU - Felker, G. Michael

AU - Cotter, Gad

AU - Filippatos, Gerasimos

AU - Greenberg, Barry H.

AU - Pang, Peter

AU - Levin, Bruce

AU - Hua, Tsushung A.

AU - Severin, Thomas

AU - Ponikowski, Piotr

AU - Metra, Marco

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Aims We studied the characteristics and clinical outcome related to diuretic response and the effects of serelaxin in patients hospitalized for acute heart failure (AHF).Methods and results RELAX-AHF was a double-blind, placebo-controlled trial, enrolling 1161 patients admitted to hospital for AHF who were randomized to 48 h i.v infusions of placebo or serelaxin (30 μg/kg per day) within 16 h from presentation. Diuretic response was defined as Δ weight kg/[(total i.v. dose)/40 mg] + [(total oral dose)/80 mg)] furosemide (or equivalent loop diuretic dose) up to day 5. Median diuretic response was -0.42 (-1.00, -0.14) kg/40 mg. A poor diuretic response was independently associated with Western-like region (Western Europe, North America, Israel, and Poland), lower diastolic blood pressure, the absence of oedema, higher blood urea nitrogen, and lower levels of aspartate aminotransferase and potassium (all P <0.01). Randomization to serelaxin was associated with lower doses of i.v. loop diuretics and slightly less weight loss, resulting in a neutral effect on diuretic response. Worse diuretic response was independently associated both with less relief of dyspnoea, measured with a visual analogue scale (VAS) at day 5 (primary endpoint; P = 0.0002), and with a higher risk of cardiovascular death or rehospitalization for heart failure or renal failure through day 60 (secondary endpoint, P <0.0001), but not with increased 180-day cardiovascular mortality (P = 0.507).Conclusions In patients hospitalized for AHF, a poor diuretic response was associated with a poor in-hospital and early post-discharge clinical outcome. Serelaxin had a neutral effect on diuretic response. Trial registration: NCT00520806.

AB - Aims We studied the characteristics and clinical outcome related to diuretic response and the effects of serelaxin in patients hospitalized for acute heart failure (AHF).Methods and results RELAX-AHF was a double-blind, placebo-controlled trial, enrolling 1161 patients admitted to hospital for AHF who were randomized to 48 h i.v infusions of placebo or serelaxin (30 μg/kg per day) within 16 h from presentation. Diuretic response was defined as Δ weight kg/[(total i.v. dose)/40 mg] + [(total oral dose)/80 mg)] furosemide (or equivalent loop diuretic dose) up to day 5. Median diuretic response was -0.42 (-1.00, -0.14) kg/40 mg. A poor diuretic response was independently associated with Western-like region (Western Europe, North America, Israel, and Poland), lower diastolic blood pressure, the absence of oedema, higher blood urea nitrogen, and lower levels of aspartate aminotransferase and potassium (all P <0.01). Randomization to serelaxin was associated with lower doses of i.v. loop diuretics and slightly less weight loss, resulting in a neutral effect on diuretic response. Worse diuretic response was independently associated both with less relief of dyspnoea, measured with a visual analogue scale (VAS) at day 5 (primary endpoint; P = 0.0002), and with a higher risk of cardiovascular death or rehospitalization for heart failure or renal failure through day 60 (secondary endpoint, P <0.0001), but not with increased 180-day cardiovascular mortality (P = 0.507).Conclusions In patients hospitalized for AHF, a poor diuretic response was associated with a poor in-hospital and early post-discharge clinical outcome. Serelaxin had a neutral effect on diuretic response. Trial registration: NCT00520806.

KW - Diuretic response

KW - Heart failure

KW - Renal function

UR - http://www.scopus.com/inward/record.url?scp=84916618655&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84916618655&partnerID=8YFLogxK

U2 - 10.1002/ejhf.170

DO - 10.1002/ejhf.170

M3 - Article

VL - 16

SP - 1230

EP - 1240

JO - European Journal of Heart Failure

JF - European Journal of Heart Failure

SN - 1388-9842

IS - 11

ER -